AAO 2019: Encouraging results revealed from early trial of subretinal gene therapy for wet AMD
October 13th 2019According to Jeffrey Heier, MD, RGX-314 administered by subretinal injection was well tolerated. In addition, it was associated with dose-dependent increase in ocular protein expression and evidence of clinical benefit.